CCR8 antagonist 1 NEW
Price | $47 | $108 | $179 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-16 |
Product Details
Product Name: CCR8 antagonist 1 | CAS No.: 723304-76-5 |
Purity: 97.33% | Supply Ability: 10g |
Release date: 2024/11/16 |
Product Introduction
Bioactivity
名稱 | CCR8 antagonist 1 |
描述 | CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 20 mg/mL (40.4 mM), Sonication is recommended. |
關鍵字 | LUN 04765 | LUN-04765 | CCR8 antagonist 1 |
相關產(chǎn)品 | AZD2098 | MLN-3897 TFA | Artemotil | CCR2 antagonist 5 | INCB-9471 | CCR3 antagonist 1 | Maraviroc | BMS-817399 | PF-4136309 | Pirfenidone | Vercirnon | CCR6 antagonist 1 |
相關庫 | 經(jīng)典已知活性庫 | 膜蛋白靶向化合物庫 | 抑制劑庫 | 腫瘤免疫治療小分子化合物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$2360.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
$1990.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
$0.00/1mg |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-04-17 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY